GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Long-Term Capital Lease Obligation

Biote (BTMD) Long-Term Capital Lease Obligation : $1.9 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biote Long-Term Capital Lease Obligation?

Biote's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.9 Mil.

Biote's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($1.8 Mil) to Dec. 2023 ($1.7 Mil) but then increased from Dec. 2023 ($1.7 Mil) to Mar. 2024 ($1.9 Mil).

Biote's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.1 Mil) to Dec. 2022 ($1.9 Mil) but then declined from Dec. 2022 ($1.9 Mil) to Dec. 2023 ($1.7 Mil).


Biote Long-Term Capital Lease Obligation Historical Data

The historical data trend for Biote's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Long-Term Capital Lease Obligation Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
- 0.38 0.13 1.93 1.68

Biote Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.78 1.76 1.68 1.92

Biote  (NAS:BTMD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Biote Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Biote's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Biote (BTMD) Business Description

Traded in Other Exchanges
N/A
Address
1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.
Executives
Mary Elizabeth Conlon officer: General Counsel C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg 10 percent owner C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc 10 percent owner 757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar officer: Chief Commercial Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar officer: Chief Financial Officer 7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer director C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris director 11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer director, officer: President and Director 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber director, officer: Chief Executive Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038

Biote (BTMD) Headlines

From GuruFocus

Biote Announces Pricing of Secondary Offering of Common Stock

By Business Wire Business Wire 01-05-2023

Biote Appoints Mary J. Puncochar as Chief Commercial Officer

By Business Wire Business Wire 05-30-2023

Biote to Present at Jefferies London Healthcare Conference

By Business Wire Business Wire 11-10-2022

Biote Reports Second Quarter 2023 Financial Results

By Business Wire 08-10-2023

Biote to Present at 35th Annual Roth Conference

By Business Wire Business Wire 03-02-2023

Biote Reports Third Quarter Financial Results

By Business Wire Business Wire 11-08-2022

Biote to Purchase Asteria Health

By Business Wire 01-17-2024